Swiss Cancer Institute presentations at ESMO 2026
The Swiss Cancer Institute will present several research contributions at the ESMO Congress 2026, taking place in Madrid from 23 to 27 October.
We present three posters on the SAKK 96/12 REDUSE trial of reduced-dose denosumab in patients with bone metastases: a translational research (TR) poster on bone turnover markers by Markus Joerger, a health economic analysis (HEA) by Elia Antonini, and a quality of life (QoL) analysis by Karin Ribi. We also present a TR poster from SAKK 08/14 by Markus Joerger (presented by Tobias Peres), and our intergroup partners present ENGOT-en23 as an oral presentation by Domenica Lorusso on October 26 (Presidential Symposium III).
Attending ESMO 2026? Visit our poster presentations to discover our latest research findings and connect with our researchers. We look forward to seeing you in Madrid!
All the details about our publications can be found here: